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INTRODUCTION
According to the national cancer statistics from 2013, breast 
cancer is the second most common cancer affecting women 
in Korea. Encouragingly, the 5-year breast cancer survival rate 
increased by 13.6% from 77.9% during 1993–1995 to 91.5% 
in 2013 due to early diagnosis and updated treatment. This 
survival rate seems almost second-to-none among developed 
countries worldwide [1]. Furthermore, the nationwide survey 
and breast cancer registry database of the Korean Breast Can-
cer Society indicated a rapid increase in breast cancer inci-
dence until 2010, followed by a gradual stabilization [2].
The Korean Breast Cancer Society has recently developed a 
Korean clinical practice guideline in response to the need for 
a more standardized and updated guideline based on the 
principle of a multidisciplinary approach to breast cancer 
treatment within the current Korean clinical situation. This 
guideline is currently under revision, leading to the seventh 
recommendation. A second consensus conference was subse-
quently held to further develop this guideline and progressed 
to pros and cons. The conference panel involved 43 experts, 
including 16 medical oncologists, 16 surgeons, two pathol-
ogists, two radiologists, and seven radiation oncologists from 
whom opinions were solicited regarding important issues re-
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The Korean clinical practice guideline recently developed by the 
Korean Breast Cancer Society to address the national clinical 
situation is currently under revision ahead of a seventh recom-
mendation. A second consensus conference was held to further 
develop this guideline by soliciting opinions regarding important 
issues related to surgery, radiotherapy, and medical oncology. 
Several issues were discussed, and the discussion progressed 
to pros and cons in the context of cases in various clinical situa-
tions. The panels discussed and voted on issues regarding sur-
gical treatment for non-axillary regional lymph nodes, regional 
nodal irradiation of pN1 disease, and ovarian functional suppres-
sion (OFS) as an adjuvant treatment in premenopausal patients 
with hormone receptor-positive breast cancer. Regarding the 
surgical treatment of non-axillary regional lymph node, most 
panelists agreed with the recommendation of preoperative che-
motherapy and postoperative radiotherapy for patients with 
biopsy-diagnosed metastases, whereas surgery or radiotherapy 
of non-axillary regional lymph nodes was suggested for clinical 
partial responders. Discussions on radiotherapy addressed the 
need for adjuvant radiotherapy and radiation field of regional 
lymph node in the context of various N1 breast cancer cases. 
The participants reached a consensus to recommend that N1 
patients should receive regional nodal irradiation for a large 
tumor burden (e.g., three positive nodes, perinodal extension, or 
large primary tumor). Finally, the panels favored OFS in addition 
to endocrine therapy for premenopausal women with high risk 
factors such as a large tumor size, involvement of more than 
three nodes, and a high histologic grade.
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lated to surgery, radiotherapy, and systemic treatment/medi-
cal oncology. The panel covered three areas, namely, surgery, 
radiotherapy, and systemic treatment. First, surgical treatment 
for non-axillary regional lymph nodes was discussed, followed 
by a panel discussion on regional nodal irradiation in patients 
with pN1 disease. Regarding systemic treatment, the panel 
members discussed whether to recommend ovarian func-
tional suppression (OFS) as an adjuvant treatment in pre-
menopausal patients with hormone receptor-positive breast 
cancer. The details of the recommendations regarding treat-
ment decisions related to these issues are provided in Supple-
mentary Table 1 (available online).
CONFERENCE HIGHLIGHTS: PANEL 
DELIBERATION
Surgical treatment issues: is surgery recommended for non-
axillary regional lymph node? 
In this conference, we discussed the surgical management 
of non-axillary regional lymph nodes, which we defined as the 
internal mammary and supraclavicular lymph nodes. We dis-
cussed the case with no distant metastasis. For cases involving 
suspicious non-axillary regional lymph nodes, approximately 
42% of the panelists answered that they would perform fine-
needle aspiration or gun biopsy to confirm an internal mam-
mary node metastasis (Q1-1), whereas more panelists agreed 
with biopsy of a suspicious supraclavicular lymph node dur-
ing the staging evaluation (Q1-2). For patients with suspicious 
non-axillary regional lymph nodes, most panelists agreed with 
the recommendation of preoperative chemotherapy (65.9% 
for the internal mammary lymph node and 78% for the supra-
clavicular lymph node) (Q1-3, Q1-4). Furthermore, more 
panelists agreed with preoperative chemotherapy if the lymph 
node metastasis had been confirmed via biopsy (fine-needle 
aspiration or gun biopsy) (Q1-5, Q1-6). 
Most panelists did not include the non-axillary regional 
lymph node during surgery if a clinically complete response 
had been achieved in this node after preoperative chemother-
apy for a biopsy-confirmed metastasis (Q1-7, Q1-8). For cases 
involving a clinical partial response in a biopsy-confirmed 
metastasis to the internal mammary lymph node, approxi-
mately half of the panel surgeons stated that they would in-
clude those nodes during mastectomy surgery (Q1-9-2), 
whereas a large proportion of surgeons would include supra-
clavicular lymph nodes with biopsy-confirmed metastasis 
during surgery (Q1-10-1, Q1-10-2). Finally, most panelists 
agreed with postoperative radiotherapy for patients with biop-
sy-confirmed non-axillary regional lymph node metastasis, 
regardless of extent of the response to neoadjuvant chemo-
therapy (Q1-13, Q1-14, Q1-15).
Radiation treatment issues: who could benefit from 
irradiation of N1 breast cancer? 
Regarding breast cancer patients with pN1 disease who un-
derwent breast-conserving surgery, 71.8% of the panelists an-
swered that regional nodal irradiation would be unnecessary. 
However, most (97.4%) still believed that irradiation should 
be performed for young patients and patients with high-grade 
disease, lympho-vascular invasion (LVI), a high positive 
lymph node ratio, positive lymph node number, extracapsular 
extension, and/or a triple-negative breast cancer status.
Most panelists (85.2%) considered the tangential field to be 
sufficient for low-risk patients undergoing radiotherapy for 
one positive node. However, 53.2% to 56.7% favored the in-
clusion of a regional lymph node along with the tangential 
field if the risk of regional recurrence had increased because 
of three-node or hormone receptor-negative disease with 
node positivity. The range of regional nodal irradiation was 
classified as including the supraclavicular lymph node only or 
including both the supraclavicular and internal mammary 
lymph nodes. 
For cases with a positive sentinel lymph node that had not 
undergone axillary lymph node dissection, the majority 
(63.3%) of participants voted that radiotherapy including the 
regional lymph node should be considered without additional 
surgery, whereas 26.7% considered axillary lymph node dis-
section followed by tangential irradiation to be superior.
Regarding pT3N1 cases treated with mastectomy, 81.1% 
agreed that all patients should undergo radiotherapy for the 
regional node. However, most panelists also agreed that add-
itional radiotherapy may not be necessary for pT2N1 cases, 
although 42.5% stated that adjuvant radiotherapy should be 
performed for high-risk patients in this group (e.g., three pos-
itive nodes).
For mastectomy cases with positive sentinel lymph node bi-
opsies, 43.7% of the panelists reported that postoperative axil-
lary radiotherapy would be sufficient without axillary lymph 
node dissection, whereas (56.3%) voted that axillary lymph 
node dissection should be performed with mastectomy.
Systemic treatment issue: is ovarian function suppression 
recommended for premenopausal patients with hormone 
receptor-positive breast cancer in an adjuvant setting? 
Before the panel discussion, two speakers reviewed the 
background knowledge regarding OFS use in hormone recep-
tor-positive premenopausal women in terms of the pros and 
cons considering the results of two large randomized phase III 
trials, namely, the Suppression of Ovarian Function Trial 
230  Seeyoun Lee, et al.
http://ejbc.kr https://doi.org/10.4048/jbc.2017.20.3.228
(SOFT) [3] and the Tamoxifen and Exemestane Trial (TEXT) 
[4]. The panel considered treatment recommendations for 
eight clinical scenarios involving cases of hormone receptor-
positive and human epidermal growth factor receptor 2 
(HER2)-negative disease at diagnosis. The first case (Q3-1) 
involved a 40-year-old woman with a grade 3, T1, node-posi-
tive tumor who developed intermittent menses after adjuvant 
chemotherapy. Approximately half of the panel (48.4%) 
agreed that this patient should receive tamoxifen with OFS. 
The next case (Q3-2) had the same biologic characteristics but 
node-negative disease and remained in premenopausal status 
after adjuvant chemotherapy. In this case, an overwhelming 
majority of the participants (87.1%) would not advise OFS for 
this patient. The third case involved a premenopausal woman 
with node-negative disease and a low-grade tumor who had 
not received adjuvant chemotherapy (Q3-3). Again, the ma-
jority of participants (71.9%) would not advise the combined 
use of OFS with tamoxifen for this patient. The fourth case 
(Q3-4) involved a 40-year-old patient with T2N1M0, grade 3 
disease, who did not have regular menses after adjuvant che-
motherapy and presented with a serum estradiol level of 10 
pg/mL and follicle-stimulating hormone level of 18 mIU/mL. 
More than half (58.6%) of the panel recommended tamoxifen 
monotherapy for this patient. 
For the fifth case (Q3-5), we used the situation from the 
fourth case but assumed that menstruation resumed during 
tamoxifen treatment to determine the impact of regular men-
ses on decisions regarding OFS use. Again, a little more than 
half of the panel (53.3%) advised against adding OFS to 
tamoxifen. The next two scenarios (Q3-6, Q3-7) involved a 
35-year-old woman with T2N2M0, grade 3 disease who re-
ceived adjuvant chemotherapy followed by tamoxifen and 
OFS. The current Korean National Insurance Service guide-
line allows OFS treatment for up to 2 years in an adjuvant set-
ting and does not coverage combination therapies comprising 
an aromatase inhibitor plus OFS for premenopausal patients. 
When asked not to consider the Korean National Insurance 
Service guideline, a majority of participants (73.3%) agreed 
that they would continue the regimen of OFS and tamoxifen 
after 2 years (Q3-6). However, when the guideline was consid-
ered (Q3-7), few participants (55.2%) preferred to continue 
OFS and tamoxifen combination therapy for this patient, and 
less than 10% of the panel recommended the use of aromatase 
inhibitor (AI) with OFS. The last case (Q3-8) involved a 
35-year-old woman with clinically T3N2M0, grade 3 disease. 
Although her tumor shrank to ypT1N1M0 after neoadjuvant 
chemotherapy, the pathology changed to estrogen receptor 
negative. Still, a majority (64.3%) of participants reported that 
they would select OFS with tamoxifen as an adjuvant endo-
crine therapy for this case. 
In summary, the panels favored OFS in addition to endo-
crine therapy for premenopausal women with high risk fac-
tors, such as a large tumor size, involvement of more than 
three nodes, and a high histologic grade. Despite the superior 
results of AI plus OFS in this high-risk group, the panel pre-
ferred tamoxifen, rather than AI, in combination with OFS. 
Furthermore, the majority of participants agreed to maintain 
OFS treatment for up to 5 years for high-risk patients. How-
ever, the extended use of OFS (more than 5 years) was not ad-
dressed at this conference.
DISCUSSION
Surgical treatment issues
Although debates regarding the surgical treatment of non-
axillary regional lymph nodes continue, most of the panelists 
at this conference agreed with the use of preoperative chemo-
therapy and postoperative radiotherapy for patients with bi-
opsy-confirmed metastases. Furthermore, many participating 
surgeons would consider surgical treatment for lymph nodes 
in cases involving clinical partial responses. Here, more sur-
geons selected additional surgery for proven non-axillary 
node metastases for cases involving the supraclavicular nodes, 
rather than the internal mammary nodes, those involving 
partial rather than complete responses to neoadjuvant chemo-
therapy, and those involving mastectomy rather than breast 
conservation surgery after preoperative systemic therapy. 
However, some surgeons also discussed the benefits of radio-
therapy for patients who achieved a partial response. These 
responses suggest that treatment decisions for such patients 
should be discussed in a multidisciplinary team setting. 
Radiotherapy issues
For breast cancer cases involving one to three positive 
pathologic lymph nodes, the primary issues involve the selec-
tion and the range of radiotherapy and radiation treatment. 
According to recently published results from the National 
Cancer Institute of Canada Clinical Trials Group MA.20 and 
EORTC 22922 trials, regional nodal irradiation significantly 
increased disease-free survival (DFS) among patients with 
breast cancer who underwent breast-conserving surgery [5,6]. 
Studies of regional nodal irradiation can be classified accord-
ing to whether patients underwent breast-conserving surgery 
or mastectomy. For the former, the whole breast is subjected 
to regional nodal irradiation, whereas with the latter, the chest 
wall is irradiated [7]. Regional nodal irradiation usually ex-
tends to the axillary apex and supraclavicular fossa, although 
the involvement of the internal mammary lymph node re-
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mains controversial [8]. 
In previous Danish and British Columbian trials, postmas-
tectomy radiotherapy (PMRT) significantly reduced the lo-
coregional recurrence rate and increased survival among pa-
tients with one to three positive nodes [9,10]. In 2014, the 
Early Breast Cancer Trialists’ Collaborative Group performed 
a meta-analysis of 8,135 patients in 22 randomized trials. 
Among the 1,314 patients with one to three positive nodes, 
the addition of PMRT resulted in a decrease of the 10-year lo-
coregional recurrence rate from 20.3% to 3.8% (p< 0.00001) 
[11]. The 10-year recurrence rate also decreased from 45.7% 
to 34.2% (p = 0.00006), although the 20-year breast cancer 
mortality rate increased from 42.3% to 50.2% (p< 0.001).
However, the benefits of PMRT for pN1 patients remain 
controversial, as these patients have a relatively low risk of lo-
coregional recurrence. Furthermore, recent therapeutic ad-
vances and increased biologic knowledge have reduced the 
benefits of PMRT for pN1 patients [12,13]. Chang et al. [14] 
found that PMRT significantly increased the DFS in a cohort 
of recently treated pN1 patients (2004–2011). Their findings 
suggest that the potential benefits of PMRT should still be 
considered, despite advances in surgical and systemic treat-
ments. However, our investigation found that only 11.9% of 
Korean women with T1–2N1 breast cancer actually received 
PMRT [15]. In this consensus conference, 80% of the panel-
ists answered that they would not advise additional radiother-
apy, similar to the current clinical practice situation. The pan-
elists also stated that N1 patients should undergo regional 
nodal irradiation for a large tumor burden (e.g., three positive 
nodes), perinodal extension, or a large primary tumor (≥ T3).
Although several studies found that risk factors such as 
high-grade tumors, estrogen receptor negativity, young age, 
high positive nodal ratio, medical location, close margins, and 
LVI could reduce survival [13], the definitions of these factors 
are heterogeneous. Therefore, whether the outcomes of re-
gional node radiotherapy are affected by risk factors remains 
unclear. The multicenter KROG 14-23 study investigated risk 
factors for recurrence in patients with N1 disease after recent 
systemic therapy without PMRT [16]. In this study, patients 
were grouped according to the number of risk factors with the 
aim of defining a subgroup that might benefit from PMRT. 
The results of the SUPREMO trial, a large randomized trial on 
the benefit of PMRT, might better stratify patients and identi-
fy those who should undergo PMRT [17].
The panelists further addressed the issue of subsequent 
treatment for patients who underwent mastectomy and had a 
positive sentinel lymph node biopsy. Here, 43.7% of the panel-
ists considered axillary radiotherapy without axillary lymph 
node dissection to be sufficient. By contrast, 57.6% of the pan-
elists from the first Korean Breast Cancer Treatment Consen-
sus conference answered that radiotherapy could replace ad-
ditional axillary lymph node dissection [18]. This discrepancy 
is attributed to differences in wording, as the relevant question 
at the first conference concerned patients who had undergone 
breast conserving surgery or mastectomy. Therefore, add-
itional time may be needed before clinicians accept the use of 
radiotherapy without additional axillary lymph node dissec-
tion, despite studies such as ACOSOG Z0011 and the AMARO 
trial [19,20].
Systemic treatment issues
For systemic treatment issues regarding OFS as an adjuvant 
treatment in patients with hormone receptor-positive pre-
menopausal breast cancer, speakers mainly discussed and 
progressed to pros and cons regarding the results of two large 
randomized phase III trials, namely, the SOFT [3] and TEXT 
[4]. The TEXT was designed to compare 5 years of tamoxifen 
therapy plus OFS versus exemestane plus OFS, whereas the 
SOFT was a three-arm trial in which 5 years of tamoxifen 
monotherapy was compared with tamoxifen plus OFS and 
exemestane plus OFS. A pooled analysis of the TEXT and 
SOFT results showed that the combined administration of an 
aromatase inhibitor with OFS significantly improved the 
5-year DFS when compared with tamoxifen plus OFS (hazard 
ratio [HR], 0.72; 95% confidence interval [CI], 0.60–0.85; 
p< 0.001). In the SOFT trial, the addition of OFS to tamoxifen 
did not improve DFS when compared with tamoxifen mono-
therapy. However, this combined regimen provided a signifi-
cant benefit relative to tamoxifen alone for women with risk 
factors for recurrence, such as lymph node metastasis and an 
age younger than 35 years (HR, 0.78; 95% CI, 0.62–0.98).
Until recently, tamoxifen was considered the standard che-
motherapeutic for premenopausal women with early hor-
mone receptor-positive breast cancer. However, the results 
from the TEXT and SOFT have led clinicians to more fre-
quently consider the addition of OFS to adjuvant tamoxifen 
or AI treatment in this population. The ECOG trial 3193 [3], 
a randomized phase III trial of tamoxifen monotherapy versus 
tamoxifen plus OFS in patients with hormone receptor-posi-
tive, node-negative disease and tumor sizes ≤ 3 cm, failed to 
demonstrate the clinical benefit of OFS, and the lack of a sig-
nificant benefit of OFS was repeatedly confirmed in low-risk 
cohorts. By contrast, the SOFT demonstrated a substantial 
benefit of OFS, that is, a reduced risk of recurrence, in a high-
risk cohort of breast cancer patients. The present conference 
panelists acknowledged that OFS could aggravate symptoms, 
such as hot flashes and sexual dysfunction, and may reduce 
the quality of life. Accordingly, they expressed great concern 
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regarding the toxicities associated with AI plus OFS regimens 
in young patients. Therefore, the panel recommended that the 
pros and cons of OFS be communicated to patients during the 
decision-making process.
CONCLUSION
Although an evidence-based recommendation was made, 
the panel had different opinions in various contexts. Discus-
sions regarding the surgical treatment of non-axillary regional 
lymph node included issues related to surgery or radiotherapy. 
Radiotherapy issues were further discussed with respect to the 
need for additional radiotherapy and the radiation field used 
to target regional lymph nodes in patients with N1 breast can-
cer. Furthermore, the panelists favored the administration of 
OFS in addition to endocrine therapy for premenopausal 
women with high risk factors, such as a large tumor size, in-
volvement of more than three nodes, and a high histologic 
grade.
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